[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pregnancy":733},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,268,0,25,[9,49,79,107,138,180,206,234,262,289,314,334,354,378,421,446,467,492,542,579,604,631,656,677,707],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053652",false,"NCT06883344","Automated Insulin for Management of Intrapartum Glycemia","Automated Insulin for Management of Intrapartum Glycemia (AIMING): a Multicenter Randomized Controlled Trial","AIMING","Inclusion Criteria:\n\n* Currently pregnant at ≥ 34 weeks\n* Known diagnosis of type 1 diabetes ≥ 1 year\n* Use of commercially available AID system since at least 28 weeks gestation\n* Singleton pregnancy\n* English- or Spanish-speaking\n\nExclusion Criteria:\n\n* Multifetal gestation\n* Planned cesarean delivery\n* Use of medications known to interfere with glucose metabolism\n* Intrauterine fetal demise\n* Physical or psychological disease likely to interfere with the conduct of the study and\u002For the ability to participate in own healthcare","FEMALE","18 Years","55 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is learn if automated insulin delivery (AID) systems can be used for glucose management during labor\u002Fdelivery for pregnant people with type 1 diabetes (T1D). The main questions this study aims to answer are\n\n* What are the neonatal glycemic outcomes with use of AID systems during labor\u002Fdelivery?\n* Do patients report higher birth satisfaction with use of AID systems during labor\u002Fdelivery?\n* Are glycemic parameters like time-in-range (TIR) better with use of AID systems during labor\u002Fdelivery?\n\nResearchers will compare AID systems to intravenous (IV) insulin (the current standard of care for glucose management during labor\u002Fdelivery) by randomly assigning participants to one or the other.",[28,29,30],"Type 1 Diabetes (T1D)","Pregnancy","Pre-Gestational Diabetes",[29,32,33,34,35],"Intrapartum glycemic management","Neonatal hypoglycemia","Perinatal care","Diabetes in pregnancy","RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2025-12-05",{"date":44,"type":22},"2028-12-31",{"name":46,"class":47},"University of California, San Francisco","OTHER",3,{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100053713","NCT06557005","Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions","Bridges to Primary Care: Transforming Postpartum Primary Care Coordination for People With Chronic Conditions","Inclusion Criteria\n\n* Receiving obstetric care at an MGH-affiliated obstetrics practice (except for the MGH HOPE Clinic, which has a unique care model that provides prenatal and postnatal care for individuals with substance use disorder, including the provision of primary care through 2+ years postpartum)\n* Pregnant with a live fetus or delivered a live-born neonate ≥24 weeks of gestation, based on the clinical estimate of gestational age\n* If postpartum, has a neonate that is currently living at the time of enrollment\n* Has one or more of the following conditions listed in the \"Problem List,\" \"Medical History,\" or clinical notes during prenatal, intrapartum, or postpartum encounters in the EHR (or in the case of BMI, the patient's anthropometric measurements):\n\n  * Chronic or essential hypertension\n  * Hypertensive disorders related to pregnancy (e.g., pre-eclampsia)\n  * Type 1 or 2 diabetes (i.e., pre-existing diabetes)\n  * Gestational diabetes\n  * Class II Obesity (pre-pregnancy body mass index ≥35 kg\u002Fm2; or if pre-pregnancy body mass index is not known, a first trimester BMI of ≥35 kg\u002Fm2)\n  * Depression or anxiety disorder\n* Has a primary care clinician listed in the patient's medical record\n* Has access to or agrees to be enrolled in the electronic health record patient portal and consents to be contacted via these modalities\n* Able to read\u002Fspeak English or Spanish language\n* Is age ≥18 years old\n\nExclusion Criteria\n\n• Any individual not meeting all inclusion criteria",{"count":56,"type":22},1320,[25],"The lack of postpartum primary care coordination is a missed opportunity to increase primary care engagement and manage chronic conditions early in life, especially for the \\>30% of pregnant people who have or are at risk for these conditions. This study aims to increase postpartum primary care engagement, quality, and experience by strengthening postpartum transitions to primary care using a behavioral economics-informed, multi-component intervention integrated into usual inpatient postpartum care. Using a randomized controlled trial and repeated outcome assessments through administrative and survey data, this study will generate rigorous, actionable evidence to ensure primary care coordination becomes standard postpartum care practice, potentially catalyzing sustained primary care engagement throughout life.",[60,61,62,29,63,64,65],"Hypertension","Diabetes","Postpartum","Anxiety","Depression","Obesity",[67,68,69,70],"Postpartum Care","Primary Care","Care Transitions","Chronic Disease",{"date":39,"type":40},{"date":73,"type":40},"2025-05-23",{"date":75,"type":22},"2028-05-23",{"name":77,"class":47},"Massachusetts General Hospital",1,{"id":80,"slug":4,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100053426","NCT07699536","Prenatal Music Exposure to Enhance Postnatal Language Development","Inclusion Criteria:\n\n* residents of the Greater Bay Area (GBA) with Cantonese and\u002For Putonghua being the primary home language(s)\n* aged 18 years or above\n* single fetus pregnancy\n* Less than 32 weeks of gestation",true,{"count":86,"type":22},480,[25],"The goal of this randomized controlled study is to evaluate the effect of prenatal music exposure on infants through two years of age.\n\nThe study addresses two primary questions:\n\n* Whether prenatal music exposure enhances neural encoding of speech and improve language and cognitive outcomes during the first two years of life among fetuses\n* Whether predictive models can be developed from available fetal data to forecast individual differences in developmental outcomes among fetuses exposed to prenatal music.\n\nParticipants will engage in music listening or self-learning five days a week until delivery. After the participants give birth, the children will be followed up on their neural responses to speech, as well as their language and cognitive development, until they reach two years of age.\n\nThe investigators will compare the effects of low- and high-dose prenatal music exposure with a control group receiving education and develop models to predict outcomes in fetuses exposed to prenatal music.",[29],[91,92,93,94,95,96,29,97],"Neural encoding","Prenatal music","Language","Cognitive","EEG","Music exposure","Predictive model","2026-07-08",{"date":39,"type":40},{"date":101,"type":40},"2025-09-15",{"date":103,"type":22},"2030-04",{"name":105,"class":47},"Chinese University of Hong Kong",2,{"id":108,"slug":4,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100054173","NCT07699978","Maternal Periodontal Inflammation and Pregnancy Outcomes: Salivary and Amniotic Biomarkers","The Relationship Between Maternal Periodontal Inflammation and Pregnancy Outcomes: Evaluation Using Inflammatory and Oxidative Stress Biomarkers in Saliva and Amniotic Fluid","Inclusion Criteria:\n\nPregnant women between 28 and 32 weeks of gestation Age 18 to 40 years Singleton pregnancy Systemically healthy Normal gestational diabetes screening (oral glucose tolerance test within the hospital reference range) Receiving only routine prenatal vitamin and iron supplementation (no therapeutic medications) Low-risk pregnancy No history of chorioamnionitis No periodontal treatment within the previous 6 months Able and willing to provide written informed consent\n\nExclusion Criteria:\n\nMultiple pregnancy Use of antibiotics or anti-inflammatory medications during pregnancy Current smoking or alcohol consumption Presence of an acute infection Placental pathology Major fetal anomaly High-risk pregnancy as determined by the obstetrician Refusal or inability to provide informed consent","40 Years",{"count":115,"type":22},80,"OBSERVATIONAL","Periodontal disease is a chronic inflammatory condition that affects the tissues supporting the teeth and may contribute to systemic inflammation and oxidative stress. Increasing evidence suggests that maternal inflammation during pregnancy may be associated with adverse pregnancy outcomes, including preterm birth. However, the biological mechanisms linking maternal periodontal inflammation to the intrauterine environment remain unclear.\n\nThis prospective observational cohort study aims to investigate the relationship between maternal periodontal status and inflammatory and oxidative stress biomarkers measured in both saliva and amniotic fluid. Eighty healthy pregnant women between 28 and 32 weeks of gestation will be recruited from the Obstetrics and Gynecology Clinic of Gulhane Training and Research Hospital. Participants will undergo a comprehensive periodontal examination and provide unstimulated saliva samples. Amniotic fluid samples will be collected during delivery as part of routine obstetric care, without any additional invasive procedures.\n\nThe concentrations of 8-hydroxy-2'-deoxyguanosine (8-OHdG), malondialdehyde (MDA), interleukin-6 (IL-6), and matrix metalloproteinase-8 (MMP-8) will be measured in saliva and amniotic fluid using enzyme-linked immunosorbent assay (ELISA). Pregnancy outcomes, including gestational age at delivery, birth weight, and pregnancy complications, will also be recorded.\n\nThe study will evaluate whether maternal periodontal inflammation is associated with changes in inflammatory and oxidative stress biomarkers in saliva and amniotic fluid and whether these biomarkers are related to pregnancy outcomes. The findings may improve understanding of the biological relationship between oral health and pregnancy and may contribute to the identification of biomarkers associated with adverse pregnancy outcomes.",[119,29,120],"Periodontal Disease","Preterm Birth",[122,29,120,123,124,125,126,127,128],"Periodontitis","Oxidative Stress","Inflammation","Saliva","Amniotic Fluid","8-Hydroxy-2'-deoxyguanosine (8-OHdG)","Interleukin-6 (IL-6)","NOT_YET_RECRUITING","2026-07-07",{"date":39,"type":40},{"date":133,"type":22},"2026-08-20",{"date":135,"type":22},"2027-08-15",{"name":137,"class":47},"Saglik Bilimleri Universitesi",{"id":139,"slug":4,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":159,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":48},"100635793","NCT07557303","Supporting Just-In-Time Consent for Prenatal Screening: The INFORM Study","Inclusion Criteria:\n\n* Currently pregnant and receiving care at a participating collaborative site - University of North Carolina, Chapel Hill; Zuckerberg Chan San Francisco General Hospital; University of Florida Health, Jacksonville.\n* 18 years of age and older\n* Able to read, speak, and understand English or Spanish\n* Has not previously been offered prenatal genetic screening for the current pregnancy\n* 24 weeks (6 months) gestational age or less\n\nExclusion Criteria:\n\n* Not pregnant, not a patient at a partner clinical site\n* Younger than 18 years of age\n* Not being able to read, speak, and understand English or Spanish\n* Has previously been offered prenatal genetic screening for the current pregnancy\n* Greater than 24 weeks gestational age (6 months)",{"count":144,"type":22},1400,[25],"This clinical trial is about prenatal genetic screening. It will test an intervention to help people make decisions about screening. The intervention is a short set of information cards about screening. This intervention is for pregnant participants. They will use the intervention on their mobile phone before they see their doctor.\n\nThe study has one main question:\n\n* Do participants who use the intervention feel more confident when they make a decision about screening?\n\nResearchers will compare participants who use the intervention to participants who do not. All participants will have their usual care when they visit their doctor.\n\nWhat will participants do?\n\n* Participants must be pregnant. They will sign up for the study before their first doctor's visit for their pregnancy. This is the visit where their doctor usually talks with them about screening.\n* Some participants will use the intervention before their first doctor's visit. Other participants will not use it.\n* All participants will talk with a researcher on the phone after their first doctor's visit.\n* Participants who use the intervention will answer a short survey on their phone.\n* A few participants who use the intervention will talk with a researcher a second time on the phone.",[148,149,150,29,151,152,153,154,155,156,157,158],"Delivery of Health Care","Genetic Testing","Humans","Noninvasive Prenatal Testing","Informed Consent","Internet-Based Intervention","Self Efficacy","Pregnant People","Decision Making","Health Education","Patient Education as Topic\u002FMethod",[160,161,162,163,164,165,166,167,168,169,170],"Non-invasive prenatal screening (NIPS)","Non-Invasive Prenatal Testing (NIPT)","Cell-free DNA (cfDNA)","Prenatal genetic screening","Informed consent","Decision making","Surveys and Questionnaires","Informed choice","Educational intervention","Decision Regret","Decision Satisfaction","2026-06-30",{"date":173,"type":40},"2026-07-01",{"date":175,"type":22},"2026-08-01",{"date":177,"type":22},"2028-06-30",{"name":179,"class":47},"Case Western Reserve University",{"id":181,"slug":4,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":84,"sex":17,"minAge":187,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":78},"100635623","NCT07555093","A Study of Multiple Micronutrient Supplementation (MMS) to Increase Adherence With Digital Technology","A Randomized Controlled Trial in Lombok: Assessing Factors Influencing Acceptance and Adherence to Multiple Micronutrient Supplementation (MMS) Using Digital Tools","SMART-MMS","Inclusion Criteria:\n\n* Pregnant women up to 32 weeks\n* Pregnant women stay in the site at least during the study period\n\nExclusion Criteria:\n\n* Lost to follow up\n* Moving to another area\n* Death\n* Abortus\n* Stillbirth","14 Years",{"count":189,"type":22},10012,[25],"The goal of this randomized clinical trial is to learn whether a digital health intervention can improve adherence to Multiple Micronutrient Supplementation (MMS) among pregnant women in Lombok Island. The study also aims to understand how individual characteristics, socio-economic factors, maternal health status, and antenatal care services influence adherence to MMS.\n\nThe main questions it aims to answer are:\n\n1. Does a digitally supported intervention increase adherence to MMS compared to standard care?\n2. Does the type of MMS packaging (bottle vs. blister) affect adherence?\n3. In the second stage, does adding calcium supplementation affect adherence to MMS?\n\nResearchers will compare four groups to see if digital support and packaging type improve MMS adherence:\n\n1. Standard care with MMS in bottles\n2. Standard care with MMS in blister packs\n3. Digital intervention with MMS in bottles\n4. Digital intervention with MMS in blister packs\n\nApproximately 10,012 pregnant women will be randomly assigned to one of these four groups using a 2×2 factorial design.\n\nParticipants will:\n\n1. Receive MMS through either bottle or blister packaging\n2. Receive either standard care or a digital health intervention (such as reminders or digital support tools)\n3. Attend routine antenatal care services\n4. Be followed throughout pregnancy, delivery, and up to 42 days after childbirth\n\nIn the second stage of the study, participants from community health posts (Posyandu) will also receive calcium supplementation in addition to MMS. Additional 900 pregnant women will be enrolled from the same Puskesmas areas participating in the MMS study to evaluate the addition of calcium supplementation. These participants will be recruited outside of the main MMS cohort and will be equally distributed across the four study arms. This stage aims to assess whether adding calcium supplementation influences adherence to MMS among pregnant women.\n\nParticipants will be monitored during pregnancy, at delivery, and during the postnatal care period up to 42 days after birth.\n\nThis study represents an early implementation of Multiple Micronutrient Supplementation (MMS) in Lombok Island, where MMS is not yet routinely available through government programs. Only selected primary healthcare centers (Puskesmas) that are randomized into the study will provide MMS to eligible participants. While the government has begun introducing MMS in other areas, it has not yet been implemented in Lombok.\n\nThe digital health intervention will only be provided to pregnant women who agree to participate in the study and provide informed consent. All participants will continue to receive standard antenatal care (ANC) services in accordance with existing government programs.\n\nThis study is also integrated with the ongoing distribution of iron and folic acid supplementation (TTD) in Lombok. Pregnant women who do not consent to participate in the study or do not receive MMS will continue to receive TTD as part of routine care outside of the study.",[29,193],"Adherence",[195,29,196,197,198],"MMS","Digitalization","adherence","Antenatal Care",{"date":173,"type":40},{"date":201,"type":40},"2026-06-13",{"date":203,"type":22},"2027-06",{"name":205,"class":47},"Summit Institute for Development, Indonesia",{"id":207,"slug":4,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":213,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":48},"100627251","NCT07446205","Poi for Mama: a Pilot to Improve Maternal Microbiome and Gestational Diabetes Risk","Inclusion Criteria:\n\n* Be at least 10 weeks into their pregnancy\n* have no pre-existing health conditions\n* Be able to read and write in English\n* be at least18 years of age\n* Own a smartphone\n* Live on the windward side of O'ahu\n* Be able to complete study activities\n\nExclusion Criteria:\n\n* Less than 10 weeks pregnant or already in third trimester\n* Have pre-existing health conditions\n* Not able to read and write in English\n* Under 18 years of age\n* Do not own a smartphone\n* Do not live on the windward side of O'ahu\n* Unable to complete study activities",{"count":212,"type":22},50,[25],"This investigator-initiated, non-randomized pilot study evaluates the effect of daily consumption of fermented poi on the maternal microbiome and gestational diabetes risk during pregnancy. Fifty pregnant participants between approximately 12 and 24 weeks of gestation will receive one pound of poi daily for four weeks, accompanied by culturally tailored nutrition education delivered via secure text messaging. Changes in vaginal, oral, and rectal microbiome composition, diet quality, gestational diabetes diagnosis, and pregnancy-related outcomes will be assessed and compared with matched controls derived from an existing cohort. This study aims to inform the feasibility and design of a larger culturally grounded dietary intervention for gestational diabetes prevention.",[216,29],"Gestational Diabetes Mellitus (GDM)",[218,216,29,219,220,221,222,223,224,225],"Gestational diabetes mellitus","Maternal microbiome","Vaginal microbiome","Fermented foods","Poi","Dietary intervention","Nutrition education","Native Hawaiian and Pacific Islander (NHPI)",{"date":227,"type":40},"2026-07-02",{"date":229,"type":40},"2026-06-12",{"date":231,"type":22},"2027-01-31",{"name":233,"class":47},"University of Hawaii",{"id":235,"slug":4,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":84,"sex":241,"minAge":242,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":252,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":78},"100630118","NCT07483515","Bonding Before Birth: A mHealth Intervention for First-time Expectant Couples","Bonding Before Birth: A Cluster-randomized, Controlled, mHealth Trial for Developing Mindfulness and Emotional Regulation in Expectant Couples","B³","Inclusion Criteria:\n\nMothers:\n\n1. 21-50 years of age\n2. Less than 20 weeks of pregnancy, confirmed by ultrasonography upon enrolment\n3. Singleton pregnancy\n4. Nulliparous\n5. Plan to deliver in Singapore\n6. Proficient and able to respond to questionnaires in English\n7. Intends for herself and her child to stay in Singapore for the next 2 years\n8. Access to a smartphone\n9. Willing to download the study app\n10. Score of 7 or more in the Edinburgh Postnatal Depression Scale\n\nFathers:\n\n1. 21-75 years of age\n2. Proficient and able to respond to questionnaires in English\n3. Intends for himself and his child to stay in Singapore for the next 2 years\n4. Access to a smartphone\n5. Willing to download the study app\n\nExclusion Criteria:\n\nMothers:\n\n1. Any pre-existing or history of psychotic depression, schizophrenia, and bipolar disorders\n2. Currently on oral\u002FIV steroids and\u002For thyroid medication\n3. History of thyroid disease\n4. Pregnant using assisted reproductive technologies\n5. Multiple pregnancies\n6. Currently enrolled in interventional randomised controlled trials\n7. Responded \"Yes, quite often\" to EPDS item 10 (\"The thought of harming myself has occurred to me\")\n\nFathers:\n\n1\\. Currently enrolled in interventional randomised controlled trials","ALL","21 Years","75 Years",{"count":245,"type":22},572,[25],"Emotional regulation is a key component of reducing parenting stress, a sense of self-efficacy, and thus successful parenting, child outcomes, and productivity amongst working parents. However, few interventions begin building these necessary components in pregnancy prior to the extremely stressful period immediately post-partum, where little trait and behavioural modification occurs. More importantly, most interventions overlook the importance of having both partners, despite fathers\u002Fpartners playing a significant role in influencing maternal stress and mood symptoms.\n\nThis goal of this study is to examine whether short weekly exercises delivered through a mobile app can help first-time parents feel better emotionally during pregnancy. These exercises are designed to help people manage their emotions and stress. Researchers want to know if doing these exercises, along with getting weekly feedback and encouragement, can reduce signs of depression and improve emotional control.\n\nExpecting mothers and fathers who are having their first child may be able to join the study if they meet certain conditions. Participants should be planning to stay in Singapore for the next two years and be comfortable using a smartphone and answering questions in English. Participants may benefit from learning new ways to manage stress and emotions, which could help improve their mental health.\n\nParticipants will wear a Fitbit watch to track activity. They will complete a short weekly survey about their well-being during pregnancy and a monthly survey about their work productivity until six months after the baby is born. They will also answer online surveys about their health, relationships, and background at the start, three times during pregnancy, and three times after birth. In addition, they will visit the research lab twice to take part in tasks that measure thinking and behaviour.",[63,29,249,250,64,251],"Parenting Self-efficacy","Stress (Psychology)","Emotion Regulation",[253,254,251,64,29,63],"Reinforcement Learning","Micro-randomization","2026-06-28",{"date":171,"type":40},{"date":258,"type":22},"2026-07-06",{"date":44,"type":22},{"name":261,"class":47},"Institute for Human Development and Potential (IHDP), Singapore",{"id":263,"slug":4,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":271,"conditions":272,"keywords":276,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":78},"100573527","NCT06747442","Culturally Engaged REcovery: MOms Connected Through Native communitY","Culturally Engaged REcovery - MOms Connected Through Native communitY (CEREMONY)","CEREMONY","CEREMONY Inclusion Criteria:\n\n* English or Spanish speaking\n* pregnant (verified by point of care urine pregnancy test)\n* plan to carry the fetus to delivery\n* identify as Indigenous, Native, Native American, American Indian or Alaska Native\n* willing to grant a release of information to allow study staff to contact other health care institutions and treatment centers and collect information from the medical record, e.g., date of delivery, infant admission etc.\n\nCEREMONY Exclusion Criteria:\n\n* have a documented psychotic episode in the last 30 days\n* be \\>39 weeks of gestation\n* be unable provide collateral contact information of at least 1 person\n* be unable to provide reliable phone number\n* plan to move within 3 months of delivery",{"count":270,"type":22},270,"Pregnant and postpartum American Indian and Alaska Native people (Native mothers) face a more than two-fold higher risk of maternal mortality compared to non-Hispanic White mothers. Deaths related to substance use (SU) and mental health conditions are a leading cause of preventable maternal mortality, including among Native mothers, making these conditions a strong target for reducing maternal mortality and morbidity. The objective of this study is to 1) adapt evidence-based perinatal care models that integrate pregnancy and postpartum care with SU treatment and care to meet the needs of Native mothers, and 2) assess the implementation and efficacy of that model for participants with substance use disorder who identify as Native receiving prenatal care at Sacred Circle Healthcare in Salt Lake City, Utah.",[273,29,274,275],"Substance Use Disorders (SUD)","Maternal Morbidity and Mortality","Cultural Adaptation",[29,277,278,279,280],"Prenatal care","Substance Use Disorder","Native and Indigenous Health","Culturally adapted care","2026-06-27",{"date":173,"type":40},{"date":284,"type":40},"2026-05-26",{"date":286,"type":22},"2029-03",{"name":288,"class":47},"University of Utah",{"id":290,"slug":4,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":84,"sex":241,"minAge":4,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":296,"conditions":297,"keywords":301,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":78},"100489688","NCT05656378","A Repository to Study Host-Microbiome Interactions in Health and Disease","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Aged \\>0 years. Only participants \\>3 years old will be seen at the NIH CC.\n* Willing to allow biological samples and data to be stored for future research.\n* Willing to provide at least one of the requested biospecimens.\n\nEXCLUSION CRITERIA:\n\n* An individual who has any condition that, in the judgment of the investigator, may put them at undue risk or make them unsuitable for participation in the study will be excluded.\n* For additional gastrointestinal and skin biopsies only, individuals on blood thinners unless they have already been stopped for the procedure.\n* For additional gastrointestinal biopsies only, individuals who have a history of gastrointestinal perforation with endoscopic biopsies will be excluded from the collection of additional gastrointestinal biopsies for the repository.\n* For additional gastrointestinal biopsies only, healthy children (\\\u003C18 years old).\n* For skin biopsies only, individuals who have a history of keloid formation.\n* For vaginal swabs and vaginal fluid only, individuals who have not started menses.\n* For breast milk only, non-lactating individuals.",{"count":295,"type":22},600,"Background:\n\nThe microbiome is the bacteria and other microorganisms that live inside and on the body. The microbiome is important for our health. Researchers study how the microbiome help people stay healthy. They study how the microbiome affects the body when people get sick. To do this research, they need samples of the microbiome living on the bodies of many people. The purpose of this natural history study is to collect microbiome samples in a repository. These samples will be used for future research.\n\nObjective:\n\nTo collect microbiome samples from the body that can be used for future research.\n\nEligibility:\n\nPeople of any age. Only those older than 3 years will be seen at the NIH clinic.\n\nDesign:\n\nParticipants will fill out a questionnaire. Topics will include their medical history and foods they eat.\n\nParticipants will be asked to give 1 or more of the following:\n\nStool, urine, saliva, vaginal fluid, and breastmilk. These samples can be collected at home and sent to the researchers.\n\nCells from participants cheek, nose, mouth, skin, rectum, and\u002For vagina. The cells may be collected by rubbing the area with a sterile cotton swab. These procedures can also be done at home.\n\nBlood. Blood may be drawn using a needle inserted into a vein in the arm. For young children, blood may be collected by a prick on the heel or finger.\n\nIntestinal tissue samples. These may be collected from participants who are having an endoscopy or colonoscopy for other reasons.\n\nSkin tissue samples. These may be collected from participants who are having biopsies for other reasons.",[298,29,299,300],"Healthy Controls","Pediatric Illnesses","Inflammatory Diseases",[302,303,304,29,305],"Microbiome","Host Response","Children","Natural History",{"date":171,"type":40},{"date":308,"type":40},"2023-03-09",{"date":310,"type":22},"2032-01-01",{"name":312,"class":313},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":315,"slug":4,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":78},"100644882","NCT07675642","The Effect of Ultrasound Visual Feedback on Birth Outcomes in Nulliparous Women With Levator Ani Muscle Co-activation at Term Pregnancy","The Effect of Ultrasound Visual Feedback on Birth Outcomes in Nulliparous Women With Levator Ani Muscle Co-activation at Term Pregnancy: A Randomized Controlled Trial","CoA_2025","Inclusion Criteria:\n\n* Nulliparous (first pregnancy)\n* Adults (≥18 years old)\n* Singleton pregnancy\n* Presence of levator ani muscle co-activation at term pregnancy (37 weeks)\n* Candidates for vaginal delivery\n* Written informed consent signed for study participation\n\nExclusion Criteria:\n\n* Presence of uterine malformations\n* Presence of fetal malformations\n* Presence of vaginal bleeding at the time of enrollment\n* Regular uterine contractions\n* Premature rupture of membranes",{"count":322,"type":22},204,[25],"The study aims to evaluate the effect of ultrasound-based visual feedback training of the pelvic floor muscles in nulliparous women at term pregnancy who present co-activation of the levator ani muscle, on the duration of the second stage of labor.\n\nThis is a single-center, no-profit, randomized controlled interventional study. Compared with standard clinical practice, patients will be enrolled at term pregnancy during routine antenatal care, when a first session of ultrasound-based visual feedback training will be performed using transperineal ultrasound.\n\nNulliparous women at term pregnancy showing co-activation of the levator ani muscle will be recruited within the standard care pathway. Participants will be randomized into two groups:\n\nGroup 1 (intervention): patients will undergo ultrasound-based visual feedback training, including real-time visualization on the ultrasound screen and explanation of the most appropriate pushing technique.\n\nGroup 2 (control): patients will receive only verbal instruction regarding the appropriate pushing technique.\n\nGiven the absence of known major confounding factors, simple randomization will be used. The randomization list will be generated electronically using the REDCap platform.\n\nRecruitment will take place in the outpatient clinics of the Obstetrics and Prenatal Medicine Unit (U.O.C) at IRCCS AOU di Bologna, Sant'Orsola Hospital. Women in the intervention group will receive two ultrasound training sessions (visual feedback) one week apart at term pregnancy. Women in the control group, after enrollment, will be informed about the phenomenon of levator ani co-activation and will receive verbal instructions on how to relax the pelvic floor muscles.\n\nAfter delivery, maternal and neonatal outcomes will be assessed, including mode of delivery, indication for operative vaginal delivery if applicable, duration of the second stage of labor, vaginal-perineal lacerations, other puerperal complications, neonatal arterial and venous pH, base excess (BE), birth weight, and neonatal intensive care unit (NICU) admission. Data will be collected through review of medical records at 40 days postpartum.",[29],"2026-06-26",{"date":171,"type":40},{"date":329,"type":40},"2026-04-22",{"date":331,"type":22},"2031-07-01",{"name":333,"class":47},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":335,"slug":4,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":78},"100625283","NCT07420621","Preliminary Effectiveness of Enhanced Text Message + Incentives","Preliminary Studies on Implementation of Smoking Cessation Interventions for Low-Income Women","Inclusion Criteria:\n\n* Pregnant women aged: 18+\n* Enrolled in the Special Supplemental Nutrition Program for women, Infants, and Children (WIC) or Medicaid (or applied\u002Fapplying)\n* Self-reported current daily smokers\n* Able to communicate in English\n* Access to a mobile phone capable of receiving text messages\n\nExclusion Criteria:\n\n* Not at all interested in quitting\n* Smoke less than 24 days in the past month\n* Greater than 30 weeks gestation",{"count":212,"type":22},[25],"This study is a preliminary evaluation of a smoking cessation intervention designed for pregnant women that combines text message support and financial incentives.\n\nThe aims of this study are to determine the preliminary feasibility and acceptability of text message + incentives (intervention) vs. text message only (control).",[344,29],"Smoking Cessation",[344,346],"Maternal Health",{"date":171,"type":40},{"date":349,"type":40},"2026-04-09",{"date":351,"type":22},"2026-08-30",{"name":353,"class":47},"University of Kansas Medical Center",{"id":355,"slug":4,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":361,"conditions":362,"keywords":366,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":106},"100524784","NCT06113237","Pregnancy Surveillance Program of Patients Exposed to Epidiolex\u002FEpidyolex During Pregnancy","Observational Pregnancy Surveillance Program of Patients Exposed to Epidiolex\u002FEpidyolex During Pregnancy to Assess the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant","Inclusion Criteria:\n\n1. Patients with exposure to at least 1 dose of Epidiolex\u002FEpidyolex during the 13 days prior to their LMP or at any time during pregnancy.\n2. Verbal or written informed consent to participate\n\nExclusion criteria:\n\n1\\) Patients exposed to a non-regulatory approved product containing Cannabidiol (CBD) during pregnancy who do not also have exposure to Epidiolex during the 13 days prior to their LMP or during the pregnancy.",{"count":212,"type":22},"The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex\u002FEpidyolex during pregnancy and their infant up to 12 months of life.",[363,364,365,29],"Maternal Complications","Pregnancy Complication","Birth Outcomes, Adverse",[367,368],"Epidiolex","Epidyolex",{"date":370,"type":40},"2026-06-29",{"date":372,"type":40},"2025-08-05",{"date":374,"type":22},"2033-08-31",{"name":376,"class":377},"Jazz Pharmaceuticals","INDUSTRY",{"id":379,"slug":4,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":23,"phases":387,"briefSummary":388,"conditions":389,"keywords":410,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":417,"leadSponsor":419,"locationsCount":78},"100586442","NCT06915428","Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities","Personalized Toolkit Building a Comprehensive Approach to Resource Optimization and Empowerment in Pregnancy & Beyond (PTBCARE+) A Randomized Controlled Trial (RCT) of Personalized Care for Prenatal Stress Reduction and Preterm Birth Disparities Prevention","PTBCARE+","Inclusion Criteria:\n\n1. Viable, singleton pregnancy, 8+0 to 19+6 weeks, dated by last menstrual period ± ultrasound using standard obstetric criteria per American College of Obstetricians and Gynecologists.\n\n   Gestational age at first ultrasound by last menstrual period (LMP) \u002F Ultrasound method \u002F Measurement agreement with LMP required • Up to 8 weeks 6 days \u002F crown rump length \u002F ± 5 days\n   * 9 weeks 0 days to 13 weeks 6 days \u002F crown rump length \u002F ± 7 days\n   * 14 weeks 0 days to 15 weeks 6 days \u002F standard fetal biometry \u002F ± 7 days\n   * 16 weeks 0 days to 19 weeks 6 days \u002F standard fetal biometry \u002F ± 10 days\n   * Gestational dating \u002F fetal viability must be confirmed by ultrasound prior to enrollment \u002F randomization.\n   * Ultrasound report must include documentation of normal fetal heart rate of ≥ 120 beats per minute, or subsequent medical record documentation of auscultation of fetal heart rate ≥ 120 beats per minute.\n   * Viability must be confirmed \u002F re-confirmed within 7 days of randomization.\n\n   If initial consent occurs early in pregnancy and V1\u002Frandomization occur later, viability must be reconfirmed to ensure ongoing eligibility prior to initiating V1 activities (including surveys) and proceeding with randomization.\n2. No signs or symptoms of, or clinical diagnosis of, evolving miscarriage, active preterm labor, preterm prelabor rupture of membranes at the time of enrollment.\n\n   * Cervical dilation at the time of enrollment is an exclusion criterion. However, cervical evaluation and digital cervical exam is not required prior to enrollment.\n\n     (3a) High a priori risk for medically indicated preterm birth - must meet at least one of the following 3 criteria (maternal medical history, prior pregnancy history, or moderate risk factor history)\n   * miPTB criteria #1: Maternal Medical History - any one of the following:\n\n     o Known chronic hypertension requiring medications in the 3 months prior to conception or prior to 22 weeks gestation.\n\n     o At least 2 blood pressure readings 6 hours apart, \\\u003C20 weeks gestation, with systolic ≥ 130 mmHg or diastolic ≥ 80 mmHg \\*regardless of need for medication or formal diagnosis of hypertension in chart\\*\n\n     o Pre-gestational diabetes mellitus.\n     * Diabetes diagnosed \\\u003C20 weeks gestation.\n     * Maternal chronic or sub-acute renal disease, including chronic kidney failure, chronic renal insufficiency, glomerulonephritis, lupus nephritis, defined as any:\n\n       \\*biopsy proven chronic renal disease history; and\u002For\n\n       \\*serum creatinine ≥ 1.1 mg\u002FdL at any time during pregnancy prior to enrollment, in the absence of other identifiable transient factors per clinician's assessment (e.g., extreme dehydration, cystitis, pyelonephritis); and\u002For\n\n       \\*chronic proteinuria, defined as baseline urine protein:creatinine ratio ≥ 0.30 mg\u002FdL or 24 hour total urine protein ≥ 300 mg in the absence of other identifiable transient factors per clinician's assessment (e.g., extreme dehydration, cystitis, pyelonephritis)\n\n       \\*Systemic Lupus Erythematosus\n       * Antiphospholipid Antibody Syndrome\n   * miPTB criteria #2: Prior pregnancy history - any ONE of the following: o Previous pregnancy complicated by preeclampsia or hypertensive disorders of pregnancy at any gestational age, in a singleton gestation; the fetus must not have had major structural anomalies or aneuploidy.\n\n     o Previous history of stillbirth ≥ 16+0 weeks in a singleton gestation; the fetus must not have had major structural anomalies or aneuploidy. The stillbirth etiology must not have been attributed to physical trauma (e.g., domestic violence, motor vehicle accident) or illicit drug use (e.g., cocaine use leading to abruption and stillbirth).\n   * miPTB criteria #3: Any two or more of the following moderate risk factors: o Nulliparity, defined as no prior pregnancy to reach at least 20 weeks gestation note that this is the traditional \u002F classic definition of 'nulliparous' and that there is overlap between nulliparity as defined this way and 'preterm birth' due to cervical insufficiency, which allows for deliveries in the 16-19 week gestational age range to be considered as 'preterm births'\n\n     o Obesity: current or pre-pregnancy body mass index ≥30 kg\u002Fm\\^2\n\n     o Family history: first degree relative with a history of preeclampsia\n\n     o Advanced maternal age: maternal age ≥ 35 years at estimated date of confinement\n\n     o Prior adverse obstetric history - one or more of the following:\n\n     \\- history of low birth weight or small for gestational age baby in a singleton gestation, defined as weight \\\u003C10% for gestational age and fetal sex; the fetus must not have had major structural anomalies or aneuploidy.\n\n     \\- history of adverse pregnancy outcome in a singleton gestation; the fetus must not have had major structural anomalies or aneuploidy.\n\n     o Long interpregnancy interval: ≥ 10 year (3650 day) pregnancy interval, defined as the time (in days) between the date of delivery of the last pregnancy to reach ≥ 20 weeks gestation and the first day of the last menstrual period for the current pregnancy.\n\n     o Black or African-American race (as a proxy for underlying racism) - self-reported. Participants who self-identify as being of more than one racial group will be considered to be of Black race for the purposes of this criterion if one of the racial groups is Black or African-American.\n     * Low socioeconomic status, defined as one or more of the following: housing or food insecurity noted in chart within the last year, self-pay or Medicaid insurance, less than high school education\n\nand\u002For\n\n(3b) High a priori risk for spontaneous preterm birth - must meet at least one of the following 2 criteria (prior pregnancy history or current pregnancy course)\n\n* sPTB criteria #1: Prior pregnancy history\n\n  * EITHER a history of a delivery of a singleton, non-anomalous baby between 16+0 and 34+6 weeks gestation or delivery of a twin, non-anomalous pregnancy between 160 \u002F7and 276 \u002F7 weeks gestation due to spontaneous preterm labor, preterm premature rupture of membranes, cervical insufficiency, or placental abruption - Chart documentation of prior preterm birth, the gestational age of the prior preterm birth (referred to as the 'qualifying delivery') should be determined. If the gestational age at delivery is obtained directly from the medical record and more than one gestational age appears, the greater of the two will be used assuming that neither is the 'source document' (i.e. an ultrasound report with a due date, a c-section report, a delivery note, etc).\n\nUse the following table as a validation of the previous delivery. For example, if the infant was male and weighed more than 2763 grams (6 pounds, 1.5 ounces) then the patient would be ineligible based on history of a preterm birth criteria. This table should only be used to determine whether the qualifying delivery is most likely to be preterm less than 35 weeks gestation when the gestational age CANNOT be verified\u002Fcalculated by review of the medical records or is not available in the medical records.\n\nGestational age 90th percentile - boys 90th percentile - girls 33 weeks \\> 2488g 5 lbs 7.8 oz \\> 2116g 4 lbs 10.6 oz 34 weeks \\> 2763g 6 lbs 1.5 oz \\> 2379g 5 lbs 3.9 oz 35 weeks \\> 3084g 6 lbs 12.8 oz \\> 2661g 5 lbs 13.9 oz\n\n* Documented history of a prior pregnancy complicated by asymptomatic cervical shortening \\\u003C25mm between 16+0 and 23+6 weeks gestation or cervical dilation ≥ 0.5cm requiring cervical cerclage placement prior to 24+0 weeks gestation, even if delivery ultimately occurred ≥ 35 weeks gestation or at term.\n\n  • sPTB criteria #2: Current pregnancy course\n* Asymptomatic cervical shortening \\\u003C25mm in the current pregnancy, diagnosed by transvaginal ultrasound that is performed ≥14+0 weeks gestation, per Registered Diagnostic Medical Sonographer(RDMS) certified Sonographer or physician with transvaginal ultrasound training program (or similar) qualifications\n* Cervical cerclage in situ in the current pregnancy due to concern for risk of preterm birth, at the discretion of the primary obstetric provider\n\n  (4) Ability to provide written, informed consent in English or Spanish\n\n  (5) Planned prenatal care at the University of North Carolina at Chapel Hill obstetrics clinics and planned delivery at the University of North Carolina Women's Hospital (Chapel Hill, NC).\n\nExclusion Criteria:\n\n1. Participation in another intervention based clinical trial during pregnancy that is deemed, at the discretion of the investigative team for the current study or the other concurrent study, to conflict with this research and\u002For confound the study results.\n\n   o There are some concurrent studies, even those designed to test an intervention, which may be compatible with the current study; this will be reviewed by the investigative leadership team on a case-by-case basis.\n2. Previous participation in the PTBCARE+ program in another pregnancy, with randomization to the PTBCARE+ (active intervention) group.\n3. Current, ongoing, illicit drug use ≥ 12 weeks gestation.\n\n   * Use of tobacco and\u002For marijuana products is not an exclusion.\n   * Receiving treatment for opioid use disorder with methadone, suboxone, or similar in an approved treatment program is not an exclusion.\n4. History of radical trachelectomy\n5. Planned voluntary termination of pregnancy.\n6. Heavy vaginal bleeding or large subchorionic hemorrhage - defined as:\n\n   * Bleeding as primary reason for unplanned clinic evaluation or emergency room visit within 14 days of potential enrollment\n   * Subjective bleeding accompanied by ≥ 4 point drop in the hematocrit within 14 days of potential enrollment\n   * Subchorionic hemorrhage or abruption on formal ultrasound with a volume ≥ 64 cubic cm (4cm x 4cm x 4cm) within 14 days of potential enrollment\n7. Major congenital anomaly such as major structural deficit of the heart, lungs, brain, or other major organ system\n\n   1. Mild renal abnormalities, clubfoot, isolated cleft lip\u002Fpalate, etc. in the fetus are not a reason for exclusion.\n   2. Isolated 'soft markers' for aneuploidy (such as choroid plexus cysts, echogenic bowel, etc.) are not a reason for exclusion.\n   3. If a major congenital anomaly is diagnosed \\*after\\* enrollment, the patient will continue to participate in the study, however, the investigators will plan to analyze the study results with and without these individuals included.\n8. Positive aneuploidy screening test (traditional biochemical assay, e.g., quad screen - risk of aneuploidy of 1:25 or higher or cell free deoxynucleic acid (DNA) test result that is screen positive for trisomy 13, trisomy 18, trisomy 21, or sex chromosome abnormality) in the absence of definitive fetal karyotype evaluation.\n\n   * Definitive fetal karyotype evaluation can only be obtained through direct testing of the tissue from the conceptus - by chorionic villus sampling or amniocentesis during pregnancy.\n   * The term \"suspected aneuploidy\" is commonly used in the medical record but this is not a diagnosis and by itself is not informative and not an exclusion criteria.\n9. Cystic hygroma or abnormally thickened nuchal translucency ≥ 3 mm at any time in the current gestation, regardless of subsequent diagnostic testing results.\n\n   * Note that a cystic hygroma remains an exclusion criterion regardless of subsequent diagnostic testing results because fetuses with this history carry an elevated risk of major congenital heart disease.\n   * Fetal echocardiogram is most accurately performed at 22-24 weeks gestation, which is later than the enrollment gestational age window.\n10. Polyhydramnios at or prior to enrollment.\n\n    o Polyhydramnios is defined as a maximum vertical pocket ≥ 8.0 cm, given that polyhydramnios \\\u003C22 weeks has a high likelihood of being associated with congenital anomalies\u002Faneuploidy and\u002For preterm birth due to preterm prelabor rupture of membranes.\n11. For potential participants who meet eligibility criteria ONLY due to prior spontaneous or medically indicated preterm birth: if the prior preterm birth was in a pregnancy complicated by twins, confirmed fetal aneuploidy, or major congenital fetal anomalies in the absence of another pregnancy meeting inclusion criteria they are not eligible.\n12. Known HIV positive with viral load greater than 1,000 copies\u002FmL or cluster of differentiation 4 (CD4) count less than 350\u002Fmm\\^3\n13. Unwillingness to undergo randomization.",{"count":386,"type":22},1228,[25],"The goal of this clinical trial is to learn if a personalized prenatal support program \\[(Personalized Toolkit Building a Comprehensive Approach to Resource optimization and Empowerment in Pregnancy \\& Beyond, (PTBCARE+)\\] works to lower stress and lower the risk of early delivery in pregnant individuals at high-risk for delivering preterm. The main question\\[s\\] it aims to answer are:\n\n* Does the PTBCARE+ patient support program lower patient-reported stress levels during pregnancy?\n* Does the PTBCARE+ patient support program improve biologic measures of stress during pregnancy?\n* Does the PTBCARE+ patient support program result in a higher chance of delivering a healthy baby at or close to full term?\n\nResearchers will compare people who participate in the PTBCARE+ patient support program to those receive usual care to see if the PTBCARE+ patient support program lowers patient-reported stress, improves biologic measures of stress, and increases the chance of delivering a healthy baby at or close to full term.\n\nParticipants will be randomly assigned to receive the PTBCARE+ patient support program or usual prenatal care.\n\nAll participants will be asked to:\n\n* complete 2 study visits during pregnancy - including completing electronic surveys, providing a blood and urine sample, measuring the heart rate variability by a clip or the ear or finger, and body composition evaluation using a simple scale-like device.\n* complete one study visit postpartum that includes completing electronic surveys, and measuring heart rate variability. Blood and urine sample collection and body composition evaluation via InBody scale are optional at the postpartum visit.\n\nPeople who are randomly assigned to receive the PTBCARE+ support program will receive several resources to help them during pregnancy. These things include items such as:\n\n* a stress reduction toolkit;\n* access to an online website that can also be downloaded as a smart phone app;\n* the option to receive an electronic massage while in clinic, and more.\n* additional support gifts provided at routine clinical appointments\n\nPeople who are randomly assigned to receive usual prenatal care will not receive any additional support resources from the study during pregnancy.",[390,120,391,392,393,394,395,396,397,398,399,29,400,401,402,403,404,405,406,407,408,409],"Preterm Birth Complication","Preterm Birth Recurrence","Preeclampsia","Preeclampsia (PE)","Hypertensive Disorders of Pregnancy","Support Program","Stress","Resilience, Psychological","Empowerment, Patient","Emotional Stress","Pregnancy Complications","Pregnancy Induced Hypertension","Neonates and Preterm Infants","Cervical Insufficiency","Social Determinants of Health (SDOH)","Cervical Shortening","Disparities in Pregnancy Complications","Disparities","Prenatal Care","Care Coordination",[383,411,412,413],"pregnancy-related disparities","patient support program","enhanced prenatal care","2026-06-25",{"date":370,"type":40},{"date":175,"type":22},{"date":418,"type":22},"2029-01",{"name":420,"class":47},"University of North Carolina, Chapel Hill",{"id":422,"slug":4,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":428,"enrollmentInfo":429,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":445},"100564382","NCT06628453","CGM for Management of Type 2 Diabetes in Pregnancy","Continuous Glucose Monitoring for Management of Type 2 Diabetes in Pregnancy","CGM2","Inclusion Criteria:\n\n* Type 2 diabetes mellitus treated with daily insulin injections or oral hypoglycemic agents diagnosed before pregnancy or at less than 14 weeks gestation with hemoglobin A1c 6.5% or greater\n* Pregnant with viable fetus at 6 to less than 23 weeks gestation\n* Maternal age 18-50 years old\n\nExclusion Criteria:\n\n* Unable or unwilling to wear CGM due to intolerance to medical-grade adhesives or skin conditions\n* Multiple gestation\n* Major fetal anomaly or two or more minor fetal anomalies\n* Planned delivery outside study consortium\n* Participating in another conflicting interventional study\n* Participation in this trial in a previous pregnancy\n* Patient unable to consent\n* Physician refusal for other reasons","50 Years",{"count":430,"type":22},564,[25],"The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are:\n\n1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose?\n2. Does continuous glucose monitoring improve maternal diabetes control and other maternal outcomes compared to self-monitoring of blood glucose?\n3. What other factors increase the risk of maternal and infant complications?\n\nParticipants will:\n\n1. Use continuous glucose monitoring or self-monitoring of blood glucose to monitor blood sugar control from enrollment until delivery\n2. Have blood drawn at enrollment, 24 weeks, 34 weeks and delivery to measure hemoglobin A1c levels and store blood for future analysis\n3. Complete surveys about social support, environmental stressors, diabetes distress and glucose monitoring satisfaction at research visits\n4. Have umbilical cord blood collected at delivery for analysis",[434,29],"Type 2 Diabetes Mellitus (T2DM)",[61,29,436],"CGM","2026-06-24",{"date":370,"type":40},{"date":440,"type":40},"2025-04-08",{"date":442,"type":22},"2029-07",{"name":444,"class":47},"University of Alabama at Birmingham",7,{"id":447,"slug":4,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":466},"100641551","NCT07661433","Prospective Evaluation of an AI Diagnostic Ultrasound Tool for Fetal Weight Estimation","Z 32503 - Prospective Evaluation of an AI Diagnostic Ultrasound Tool for Fetal Weight Estimation","Inclusion Criteria:\n\n* 18 years of age or older\n* Viable intrauterine pregnancy\n* Delivery expected within one week of study procedures between 24 0\u002F7 and 42 6\u002F7 weeks, including participants with a scheduled induction or cesarean delivery on a known date, or those admitted in spontaneous labor\n* Ability and willingness to provide written informed consent\n* Willingness to comply with all study procedures\n\nExclusion Criteria:\n\n* Maternal body mass index ≥ 40 kg\u002Fm\\^2\n* Multiple gestation (i.e., twins or higher order)\n* Known major fetal malformation or anomaly\n* Any maternal condition (medical, psychological, or social) that, in the opinion of the study team, may interfere with study participation or data integrity.",{"count":453,"type":22},1000,"Purpose: The primary objective of this study is to assess the diagnostic accuracy of an AI-enabled ultrasound tool for estimating fetal weight Participants: 1,000 pregnant individuals Procedures (methods): This prospective diagnostic accuracy study will enroll 1,000 pregnant individuals within one week of anticipated delivery. At a single visit, each participant will undergo two ultrasound assessments: (1) standardized sweeps for AI analysis (performed by both specialist and nonspecialist users), (2) specialist-performed fetal biometry.",[456,29,457,458],"Fetal Weight","Machine Learning","Pregnancy - Prenatal Testing","2026-06-22",{"date":414,"type":40},{"date":462,"type":22},"2026-06",{"date":464,"type":22},"2026-12",{"name":420,"class":47},5,{"id":468,"slug":4,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":23,"phases":476,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":491},"100408852","NCT04603859","When to INDuce for OverWeight? (WINDOW)","When to INDuce for OverWeight? - a Randomised Controlled Trial (WINDOW)","WINDOW","Inclusion Criteria:\n\n• Pregnant women with pre- or early pregnancy BMI ≥ 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Legal or ethical considerations: maternal age \\\u003C18 years, language difficulties requiring an interpreter or translator\n* Multiple pregnancy\n* Previous caesarean section\n* Uncertain gestational age, defined as gestational age determined by other measurements than the Crown-Rump length (CRL) Measurement\n* Planned elective caesarean section at time of randomisation\n* Fetal contraindications to IOL at time of randomisation: e.g. non-cephalic presentation, or other fetal conditions contraindicating vaginal delivery\n* Fetal contraindications to expectant management at time of randomisation\n* Maternal contraindications to IOL at time of randomisation: e.g. placenta previa\u002Faccreta, vasa previa\n* Maternal contraindications to expectant management at time of randomisation: e.g. maternal medical conditions, ultrasonically diagnosed oligohydramnios (DVP\\\u003C 2 cm), signs of labour including pre-labour rupture of membranes (PROM)",{"count":475,"type":22},1900,[25],"The rate of overweight and obese women becoming pregnant is increasing. Obesity in pregnancy along with delivery by cesarean section in obese women is associated with several complications as compared to normal weight women. The longer the woman is pregnant, the longer she is at risk. In an otherwise low-risk pregnant woman at term, it is an ongoing clinical dilemma, whether the benefits of elective induction of labor and termination of the pregnancy will outweigh the potential harms from concomitant induction and delivery process. The proposed study is a randomized controlled study of elective induction versus expectant management in obese women. The study will be carried out as a national multicenter study with inclusion of 1900 participants from Danish delivery wards. The null hypothesis is that the caesarean section rate is similar with elective induction of labor at 39 weeks of gestation, compared with expectant management among pregnant women with pre- or early pregnancy BMI≥30.",[29,65,479],"Parturition",[481,482,483],"Induction of labor","Expectant management","Cesarean section",{"date":326,"type":40},{"date":486,"type":40},"2020-10-19",{"date":488,"type":22},"2026-07",{"name":490,"class":47},"University of Aarhus",12,{"id":493,"slug":4,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":502,"conditions":503,"keywords":511,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":538,"completionDateStruct":539,"leadSponsor":541,"locationsCount":78},"100643915","NCT07667647","MoDi Twin Placental Imaging","Healthy Monochorionic Diamniotic Twin Microvasculature and Placental Imaging","Inclusion Criteria:\n\n1. Subject is 18 to 45 years of age at screening\n2. Non-anomalous, monochorionic, diamniotic (MoDi) or monochorionic, monoamniotic (MoMo) twin gestation without suspected genetic disorders\n3. Low-risk aneuploidy screening, if performed\n4. Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC)\n5. Anatomical survey has been performed\n6. 18 - 26 weeks gestational age\n\n8\\. Subject willing and able to provide\u002Fre-provide informed consent\n\nExclusion Criteria:\n\n1. Suspected fetal genetic disorder(s)\n2. Suspected fetal infection(s), twin-twin transfusion syndrome (TTTS), twin reversed arterial perfusion sequence (TRAPS), or maternal vascular disease\n3. Non-English reading and speaking\n4. Unstable housing or transportation\n5. Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment","45 Years",{"count":500,"type":22},10,[25],"Twin-twin transfusion syndrome (TTTS) can arise in monochorionic, diamniotic (MoDi), those identical twins arising from division of a single fertilized ovum at 4-8 days gestational age (GA) or monochorionic, monoamniotic (MoMo or Mono-Mono) twins, arising from division on day 8-13 GA.\n\nIn monochorionic twin pregnancies sharing a single placenta often unevenly, anastomoses \\[connections\\] artery to artery (AA), vein to vein (VV), and artery to vein (AV) can occur.\n\nAV anastomoses usually flow unilaterally, shunting blood unevenly towards one twin and away from the other. This can lead to fluid overload and polyhydramnios along with many other pathologies in one twin while the other twin suffers from inadequate blood flow and oligohydramnios, along with secondary pathologies arising from these conditions.\n\nTTTS will affect approximately 8-10% of MoDi twins while 6% of MoMo twins will suffer with this condition.\n\nTreatment for TTTS is necessary, with the donor or 'pump' twin having around an 80% chance of death without medical intervention.\n\nThe aim of this single arm, unblinded, feasibility study of the Verasonics Vantage 256 device is to leverage the devices ultrafast power Doppler imaging (uPDI) to perform microvascular mapping of the placenta in healthy, non-anomalous, 18-26 week gestational age (GA), monochorionic, diamniotic (MoDi) or monochorionic, monoamniotic (MoMo\u002FMonoMono) pregnancies without TTTS, twin reversed arterial perfusion sequence (TRAP), or maternal vascular disease.\n\nParticipants will be recruited in the Maternal Fetal Medicine department of Carilion Clinic, which specializes in high risk or complicated pregnancies. Pregnant subjects carrying monochorionic twins and scheduled for appointments at the clinic, who meet study eligibility criteria, will be approached between weeks 18 and 26 for study enrollment.\n\nThose providing informed consent will undergo a single, transabdominal ultrasound examination by a licensed ultrasonographer or obstetrician with the Verasonics Vantage 256 ultrasound machine, with imaging focused on mapping the vasculature of the placenta with ultrafast power Doppler imaging (uPDI). The ultrasound exam will last about 15 minutes and occur immediately after the subject's standard-of-care appointment at the clinic so as not to inconvenience subjects more than necessary. Similar to commercially marketable ultrasounds in the US, the Verasonics ultrasound will use the principle of 'As Low As Reasonably Achievable (ALARA) to output the lowest acoustic waves possible to achieve the ultrasound imaging.\n\nAfter the single ultrasound scan, subjects' electronic medical records will be used to source demographic, medical, obstetric, and other historical datapoints to better characterize the 10-subject study population and their babies.\n\nNo follow-up contact with subjects is expected after the single research ultrasound visit.",[504,505,506,507,508,29,509,510],"Monochorionic Diamniotic Placenta","Monochorial Monoamniotic Placenta","Monochorionic Twins","Ultrasound Doppler","Ultrasound","Twin Pregnancy, Monochorionic","Twin Twin Transfusion Syndrome",[512,513,514,515,516,29,517,518,519,520,521,522,523,524,525,526,510,527,528,529,530,531,532,533,508,534,535,408],"Carilion Clinic","Maternal Fetal Medicine","Obstetrics","OB","OBGYN","Twin Pregnancy","Whitham","Monochorionic","Monochorionic Diamniotic","MoDi","MoMo","Monochorionic Monoamniotic","Twin","TTTS","Twin-Twin Transfusion Syndrome","uPDI","ultrafast power Doppler Imagine","Quantitative Ultrasound","QUS","Fetoscopic laser photocoagulation","FLP","Verasonic","Doppler","Doppler Imaging","2026-06-19",{"date":414,"type":40},{"date":173,"type":22},{"date":540,"type":22},"2029-07-01",{"name":512,"class":47},{"id":543,"slug":4,"hasResults":11,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":548,"enrollmentInfo":549,"targetDuration":4,"studyType":23,"phases":551,"briefSummary":552,"conditions":553,"keywords":560,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":78},"100635054","NCT07547696","CARRII Native Intervention Optimization Trial","CARRII Native Intervention Optimization Trial 3-month Factorial Experiment With 512 Participants Randomized to 8 Conditions","Inclusion Criteria:\n\n* Native American\u002FAmerican Indian\u002FAlaska Native,\n* who are not surgically sterile,\n* who report alcohol consumption at risk levels and risk for pregnancy in the past 90 days due to having sex with a man with inconsistent, ineffective, or no contraception.\n* Participants must have access to the Internet via a mobile device they can access daily\n\nExclusion Criteria:\n\n* cognitive disorders including mental retardation, dementia, or psychotic disorders that could impair ability to understand the intervention material or give informed consent.","44 Years",{"count":550,"type":22},512,[25],"The purpose of this study is to identify the best combination of new intervention components to use with CARRII, the first automated online intervention for alcohol-exposed pregnancies (AEP). This intervention is specifically designed for Native women and others who can become pregnant. Our goal is to maximize the effectiveness of the online intervention while keeping costs manageable for Native communities.",[554,29,555,556,557,558,559],"Fetal Alcohol Spectrum Disorders","Alcohol-Related Disorders","Drinking, Alcohol","Contraception Behavior","Alcohol Exposed Pregnancy","Sexual Behavior",[561,562,563,564,565,566,567,568,569],"Native American","female","adult","contraception","alcohol","digital intervention","mobile health (mHealth)","optimization","risk reduction","2026-06-18",{"date":572,"type":40},"2026-06-23",{"date":574,"type":40},"2026-06-02",{"date":576,"type":22},"2028-07-30",{"name":578,"class":47},"University of Virginia",{"id":580,"slug":4,"hasResults":11,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":588,"conditions":589,"keywords":591,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":597,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":78},"100519930","NCT06049953","Maternal And Infant Antipsychotic Study","Developmental Effects of Antenatal Exposure to Antipsychotics","MAIA","Inclusion Criteria:\n\n* Pregnant\n* Severe mental illness, including:\n\n  * Psychotic disorder (affective and nonaffective)\n  * Bipolar disorder\n  * History of psychiatric hospitalization, regardless of diagnosis\n* Able to complete study interviews and measures in English, Dutch, or Spanish\n\nExclusion Criteria:\n\n* Active substance use disorder in pregnancy\n* Insufficiently high-functioning to provide full informed consent and\u002For participate in study procedures",{"count":587,"type":22},74,"The goal of this observational study is to learn about maternal psychiatric course and infant development in pregnant individuals with severe mental illness, comparing those treated with antipsychotics to those treated with other medications or without medication. The main questions it aims to answer are:\n\n1. Is risk of psychiatric relapse different among individuals who take antipsychotic medication, other medication, or no medication?\n2. Are pregnancy and neonatal health outcomes different among individuals who take antipsychotic medication, other medication, or no medication?\n3. Do infant behavior and neurodevelopment differ among babies who were exposed to antipsychotic medication, other medication, or no medication in utero? Participants will\n\n   * complete a psychiatric interview and questionnaires while pregnant;\n   * donate blood from the mother and from the umbilical cord at delivery\n   * have their babies participate in infant behavior evaluations and an EEG procedure.\n\nResearchers will compare these outcomes among individuals who were treated either with antipsychotic medication, with psychotropic medications of other classes, and with no medication, to see if psychiatric benefits for the mother and health outcomes for mother and child differ among these three types of treatment.",[590,29],"Antipsychotics",[592,593,594,595,596],"antipsychotic","pregnancy","severe mental illness","neonatal adaptation syndrome","neurodevelopment",{"date":459,"type":40},{"date":599,"type":40},"2023-09-29",{"date":601,"type":22},"2028-01-01",{"name":603,"class":47},"Icahn School of Medicine at Mount Sinai",{"id":605,"slug":4,"hasResults":11,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":609,"eligibilityCriteria":610,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":23,"phases":613,"briefSummary":614,"conditions":615,"keywords":617,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":78},"100641438","NCT07657000","Physical Activity in Bed Rest Hospitalized High-Risk Pregnant Women.","Physical Activity in Bed Rest Hospitalized High-Risk Pregnant Women","BedRest-1","Inclusion Criteria:\n\n* Maternal age of 18 or more\n* Delivery not expected within 1 week after recruitment.\n* Language ability to understand the study.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Fetal death\n* Severe mental health disorders and substance abuse disorders.",{"count":612,"type":22},140,[25],"This study aims to evaluate the impact of a specifically designed exercise program for hospitalized high-risk pregnant individuals on bed rest. This is a specifically designed physical activiity program, consisting of a resistance and strength exercises intended to be performed even while in bed and seeks to address physical and emotional health challenges during hospitalization. The study will compare outcomes between participants who follow the exercise program and those receiving standard care. Primary outcomes include physical and emotional health parameters, quality of life, and sleep quality. Secondary outcomes focus on feasibility, adherence, and participant satisfaction. This research addresses the gap in physical activity guidelines for pregnant individuals on bed rest and explores the potential benefits of exercise to improve maternal well-being and postpartum recovery.",[616,29,400],"Bed Rest",[618,29,619,620,621,622],"Bed rest","Pregnancy complications","Hospitalization","Exercise","Exercise adaptations","2026-06-17",{"date":570,"type":40},{"date":626,"type":22},"2026-09",{"date":628,"type":22},"2029-09",{"name":630,"class":47},"Hospital Clinic of Barcelona",{"id":632,"slug":4,"hasResults":11,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":11,"sex":241,"minAge":18,"maxAge":4,"enrollmentInfo":638,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":640,"conditions":641,"keywords":642,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":650,"startDateStruct":651,"completionDateStruct":652,"leadSponsor":654,"locationsCount":4},"100624387","NCT07408973","Prospective Twin Pregnancy Cohort at Montpellier University Hospital","Twin Pregnancy Cohort at Montpellier University Hospital for a Study of the Impact of the Exposome: Pilot Study","COGEM","Mother's inclusion Criteria:\n\n* Patient of legal age (≥ 18 years)\n* Patient pregnant with a twin pregnancy ≥ 25 weeks of gestation\n* Pregnancy initially twin, triplet, or quadruplet, progressing to a twin pregnancy after spontaneous or medical embryo reduction, or after selective termination of pregnancy\n* Delivery planned at Montpellier University Hospital\n\nTwins' inclusion Criteria:\n\n* Twins born in a twin pregnancy ≥ 25 weeks of gestation\n\nMother's exclusion Criteria:\n\n* Pregnant woman with at least one fetus presenting with a chromosomal or genetic abnormality or a polymalformative syndrome, and for whom early postnatal death is anticipated.\n* Planned travel preventing the study from being completed\n* Failure to obtain informed and written consent from the patient for participation in the study and the collection of biological samples\n* Patient unable to read and\u002For write French\n* Patient unable to understand and\u002For speak French\n* Patient not benefiting from a national health insurance scheme\n* Person under legal protection, guardianship or curatorship\n* Person participating in other interventional research study\n\nTwins' exclusion Criteria:\n\n* Mother's absence from or withdrawal from the study\n* Birth in a facility other than Montpellier University Hospital\n* One or two children under guardianship\n* Lack of informed and written consent from legal representatives\n* One of the two fetuses is expected to die\n* Lack of informed and written consent from the prospective parent(s) for participation in the study and the collection of biological samples\n* Parents unable to read and\u002For write French\n* Parents not understanding and\u002For speaking French",{"count":639,"type":22},360,"This prospective observational cohort study aims to investigate the impact of the maternal and early-life exposome on neonatal and early childhood health outcomes in twin pregnancies followed at University Hospital of Montpellier (France). Grounded in the Developmental Origins of Health and Disease (DOHaD) framework, the study focuses on how environmental, biological, and lifestyle exposures during pregnancy and the first year of life influence fetal growth, neonatal health, and early development.\n\nA total of 120 women with monochorionic or dichorionic twin pregnancies and their 240 children will be included. Maternal exposome assessment includes air pollution exposure, lifestyle, diet, medical history, and biological measurements. Neonatal outcomes, including abnormal birth weight, will be evaluated at birth, and children will be followed until one year of age to assess growth, health events, and developmental outcomes. Biological samples collected at different times during the study will allow the assessment of chemical exposures and epigenetic markers. This study aims to generate original French twin pregnancy data and to improve understanding of environmental determinants of early-life health.",[29,524],[643,644,645,646,647,648,649],"Exposome","Air Pollutants","Lead","Diet, Food, and Nutrition","Healthy Lifestyle","Obstetric Labor Complications","Children Health",{"date":570,"type":40},{"date":464,"type":22},{"date":653,"type":22},"2030-12-01",{"name":655,"class":47},"University Hospital, Montpellier",{"id":657,"slug":4,"hasResults":11,"nctId":658,"briefTitle":659,"officialTitle":660,"acronym":661,"eligibilityCriteria":662,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":663,"targetDuration":4,"studyType":23,"phases":665,"briefSummary":666,"conditions":667,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":670,"startDateStruct":671,"completionDateStruct":673,"leadSponsor":675,"locationsCount":106},"100600948","NCT07104123","Substance Use in Pregnant People - Optimizing Retention in Treatment","Substance Use in Pregnant People - Optimizing Retention in Treatment by Maximizing Opportunities for Management","SUPPORT-MOM","Inclusion Criteria:\n\nConfirmed viable intrauterine pregnancy at any gestational age, or within three years postpartum\n\nSUD as defined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders or clinician documentation\n\nExclusion Criteria:\n\nDecline follow-up care at study site\n\nRequire immediate hospitalization for unstable medical or psychiatric conditions making them clinically unsuitable to participate in a research study",{"count":664,"type":22},40,[25],"Substance use during pregnancy is a leading cause of maternal morbidity and mortality in the United States, with 55-80% of postpartum patients disengaging from substance use disorder (SUD) treatment within one year of delivery. Structural and social determinants of health, including housing instability, transportation barriers, and limited childcare access, further exacerbate disparities in treatment retention.\n\nThis pilot study, conducted in two specialized prenatal care clinics, evaluates the feasibility and acceptability of two integrated strategies to promote sustained engagement in recovery-oriented services during the perinatal and postpartum periods. Aim 1 implements a standardized social needs screening and referral protocol to connect patients with community-based supports. Aim 2 pilots a contingency management intervention to incentivize recovery-supportive behaviors.\n\nFindings will inform the design of a larger multi-site randomized controlled trial to evaluate the impact of these interventions on treatment retention, overdose prevention, and maternal-infant health outcomes.",[668,29,62,669],"Substance Use Disorder (SUD)","Contingency Management",{"date":459,"type":40},{"date":672,"type":40},"2026-02-02",{"date":674,"type":22},"2027-09",{"name":676,"class":47},"Washington University School of Medicine",{"id":678,"slug":4,"hasResults":11,"nctId":679,"briefTitle":680,"officialTitle":681,"acronym":682,"eligibilityCriteria":683,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":684,"targetDuration":4,"studyType":23,"phases":686,"briefSummary":687,"conditions":688,"keywords":692,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":699,"lastUpdatePostDateStruct":700,"startDateStruct":701,"completionDateStruct":703,"leadSponsor":705,"locationsCount":78},"100641373","NCT07660471","Mindfulness-Based Intervention in Primiparous Pregnant Women","Effect of a Mindfulness-Based Intervention on Childbirth Self-Efficacy, Fear of Childbirth, and Self-Compassion in Primiparous Pregnant Women: A Randomized Controlled Trial","MBCP","Inclusion Criteria:\n\n* Pregnant women aged 18 years and older\n* Primiparous women\n* Singleton pregnancy\n* Gestational age between 28 and 32 weeks\n* No known obstetric complications\n* Ability to read and understand Turkish\n* Attendance at the Pregnancy School of the Healthy Life Center\n* Willingness to participate and provide written informed consent\n* Willingness to participate in the mindfulness-based intervention program\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* High-risk obstetric complications (e.g., preeclampsia, gestational diabetes, placenta previa)\n* Diagnosed severe psychiatric disorders (e.g., psychotic disorders, bipolar disorder)\n* Substance or alcohol dependence\n* Previous participation in a structured mindfulness, meditation, or similar awareness-based program\n* Inability to attend intervention sessions regularly",{"count":685,"type":22},128,[25],"This randomized controlled trial aims to evaluate the effect of a mindfulness-based intervention on childbirth self-efficacy, fear of childbirth, and self-compassion among primiparous pregnant women. Eligible pregnant women will be randomly assigned to either a mindfulness intervention group or a control group receiving routine antenatal education and standard prenatal care. The intervention program will consist of eight sessions delivered over four weeks. Outcomes will be assessed before and after the intervention using validated measurement tools. The findings may contribute to the development of effective psychosocial interventions to improve maternal well-being during pregnancy.",[29,689,690,691],"Fear of Childbirth","Childbirth Self-efficacy","Self-Compassion",[693,694,29,695,689,696,691,697,698],"Mindfulness","Mindfulness-Based Intervention","Primiparous Pregnant Women","Childbirth Self-Efficacy","Maternal Mental Health","Randomized Controlled Trial","2026-06-16",{"date":459,"type":40},{"date":702,"type":22},"2026-06-01",{"date":704,"type":22},"2026-10-31",{"name":706,"class":47},"Agri Ibrahim Cecen University",{"id":708,"slug":4,"hasResults":11,"nctId":709,"briefTitle":710,"officialTitle":711,"acronym":4,"eligibilityCriteria":712,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":498,"enrollmentInfo":713,"targetDuration":4,"studyType":23,"phases":715,"briefSummary":716,"conditions":717,"keywords":720,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":726,"lastUpdatePostDateStruct":727,"startDateStruct":728,"completionDateStruct":729,"leadSponsor":731,"locationsCount":78},"100642197","NCT07658989","Optimizing Anticoagulation in Pregnancies With Mechanical Heart Valves","A Prospective Multicenter Cohort Pilot Study Comparing Antithrombotic Regimens in Pregnancies With Mechanical Heart Valves","Inclusion Criteria:\n\n1. Pregnant individuals with one or more MHVs\n2. Who consent to participate\n3. Are 18 years or older and\n4. Less than 12 weeks gestation\n\nExclusion Criteria:\n\n1. Have a platelet count less than 50 x 10(9)\u002FL as there is an increased risk of bleeding with thrombocytopenia, and\u002For\n2. Have active bleeding defined as bleeding resulting in a hemoglobin reduction ≥10 g\u002FL or in hemodynamic instability.\n3. Have new valve thrombosis identified immediately prior to pregnancy",{"count":714,"type":22},100,[25],"The purpose of this pilot study is to collect data on pregnancies with mechanical heart valves to see if using a blood thinner called low molecular weight heparin (LMWH) and low dose aspirin (LDA) is comparable to warfarin\u002Fvitamin K antagonist (VKA) to reduce the chance of clotting around the mechanical valve and improve survival. The study is a pilot study as the study investigators need to ensure that the blood levels needed for adequate amounts of LMWH and warfarin can be maintained during pregnancy to be able to compare LMWH and aspirin to warfarin. If this study shows that we can collect the tests that are needed for a larger study, the individuals' information who participated in this pilot study will be moved to the larger study. The larger study will compare survival, clot development and cardiac function as well as safety of these two common blood thinners.",[29,718,719],"Prosthetic Heart Valve","Anticoagulant Therapy",[29,721,722,723,724,725],"Prosthetic heart valve","Anticoagulant therapy","Low molecular weight heparin","warfarin","vitamin K antagonist","2026-06-15",{"date":459,"type":40},{"date":284,"type":40},{"date":730,"type":22},"2030-12",{"name":732,"class":47},"Mount Sinai Hospital, Canada",""]